<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02184689</url>
  </required_header>
  <id_info>
    <org_study_id>DNDiHATFEX006</org_study_id>
    <nct_id>NCT02184689</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study</brief_title>
  <official_title>Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drugs for Neglected Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Drugs for Neglected Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the efficacy and safety of an oral regimen of fexinidazole
      (once daily for 10 days) in the treatment of stage 1 and stage 2 T.b. gambiense sleeping
      sickness in children at least 6 years old and over 20 kg bodyweight.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outcome (success or failure) at the test of cure (ToC)</measure>
    <time_frame>12 months after the end of treatment</time_frame>
    <description>Success at 12 months, adapted from the WHO criteria (51), is defined as a cured patient:
Patient alive;
AND no evidence of trypanosomes in any body fluid;
AND WBC ≤20/µL in CSF.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Human African Trypanosomiasis (HAT)</condition>
  <arm_group>
    <arm_group_label>Fexinidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fexinidazole</intervention_name>
    <arm_group_label>Fexinidazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent form signed by one of the parents or the child's legal representative

          -  Child assent to participate in the study collected in the presence of an impartial
             witness

          -  Age between 6 and 15 years old

          -  &gt; 20 Kg bodyweight

          -  Boy or girl

          -  Able to ingest at least one complete meal per day (or at least one Plumpy'Nut® sachet)

          -  Able to swallow 600mg fexinidazole tablets

          -  Karnofsky index &gt; 50

          -  Presence of trypanosomes in blood and/or lymph and/or CSF

          -  Permanent address and ability to comply with follow-up visit schedule

        Exclusion Criteria:

          -  Child refusing to be included in the trial

          -  Bodyweight &lt; 20 Kg

          -  Severe malnutrition, defined as having a BMI below 16 (- 2 Z-score of the norm
             according to WHO 2007 Growth reference data)

          -  Inability to take oral medication

          -  Pregnancy or breastfeeding

          -  Clinically relevant medical condition other than HAT that, in the Investigator's
             opinion, may jeopardize subject safety or interfere with participation in the study,
             including but not limited to significant liver or cardiovascular disease, active
             documented or suspected infection, central nervous system (CNS) trauma or seizure
             disorders, coma or altered consciousness

          -  Severely deteriorated general condition, such as cardiovascular shock, respiratory
             distress, or terminal illness

          -  Any medical condition (except HAT-specific symptoms) hindering communication with the
             Investigator as required for the completion of this study

          -  Any contraindication to imidazole products (known hypersensitivity to imidazoles)

          -  History of HAT treatment in the past 2 years

          -  Patients previously enrolled in the study or having already received fexinidazole.

          -  Expected follow-up difficulties (migrants, refugees, itinerant vendors, etc.).

          -  Current alcohol or drug abuse

          -  Clinically significant abnormal laboratory findings, including ASAT and/or ALAT &gt; 2
             times ULN // Total bilirubin &gt; 1.5 times ULN // Severe leukopenia (&lt; 2000/mm3) //
             Potassium (K+) &lt; 3.5 mmol // Any other clinically significant abnormal laboratory
             value (see details in Investigator Manual)

          -  Pregnancy confirmed by a positive urine pregnancy test obtained within 24 hours (h)
             prior to start of study treatment (see Section 5.8.3 Contraception; p36) for girls
             over 12 years old and over

          -  ECG abnormalities assessed by a central cardiologist

          -  QTcF≥ 450 ms, as measured automatically (if first measurement is abnormal, a second
             assessment will be done at least 10-20 min later, with the patient in resting
             position).

          -  Patients not tested for malaria and/or not treated adequately for this infection

          -  Patients not treated adequately for soil transmitted helminthic diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2014</study_first_submitted>
  <study_first_submitted_qc>July 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trypanosomiasis</mesh_term>
    <mesh_term>Trypanosomiasis, African</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

